BACKGROUND: There is scarcity of data regarding invasive mold infections (IMIs) in children with cancer. METHODS: We retrospectively identified patients (18 years old or younger) with malignant disease who developed proven or probable IMIs (European Organization for Research on the Treatment of Cancer/Mycoses Study Group criteria) during a 10-year period (1998-2008). We reviewed their risk factors and clinical characteristics and assessed their crude mortality rates and treatment outcomes 12 weeks after IMI diagnosis. RESULTS: Forty-eight patients (30 males) were identified, 30 (63%) of whom had a proven IMI. The most prevalent mold were Aspergillus species (40%), followed by Mucorales (20%) and Fusarium species (11%). Acute leukemia was the most common underlying malignancy (39 patients, [81%]). Twenty-three (59%) of them had refractory leukemia. Neutropenia was present at the day of IMI diagnosis in 67% of the patients. Sixty-two percent of the patients received prior corticosteroids. The dominant site of infection was the lungs (79%), followed by skin (29%) and sinuses (10%). Seventy-one percent of patients had radiological findings suggestive of fungal pneumonia (either nodules or masses). The mainstay of antifungal therapy was a lipid formulation of amphotericin B. Antifungal therapy resulted in 54% response rate (33% complete) at 12 weeks. The crude 12-week mortality rate was 31%. Logistic regression analysis demonstrated that monocytopenia (P = .013), malnutrition (P = .012), and intensive care admission in the month prior to IMI diagnosis (P = .027) were risk factors for death within 12 weeks. CONCLUSIONS: Although Aspergillus spp. was the most common mold in our pediatric cancer population, the epidemiology of the IMIs was diverse. Adults and children share similar risk factors for and epidemiology of IMIs.
BACKGROUND: There is scarcity of data regarding invasive mold infections (IMIs) in children with cancer. METHODS: We retrospectively identified patients (18 years old or younger) with malignant disease who developed proven or probable IMIs (European Organization for Research on the Treatment of Cancer/Mycoses Study Group criteria) during a 10-year period (1998-2008). We reviewed their risk factors and clinical characteristics and assessed their crude mortality rates and treatment outcomes 12 weeks after IMI diagnosis. RESULTS: Forty-eight patients (30 males) were identified, 30 (63%) of whom had a proven IMI. The most prevalent mold were Aspergillus species (40%), followed by Mucorales (20%) and Fusarium species (11%). Acute leukemia was the most common underlying malignancy (39 patients, [81%]). Twenty-three (59%) of them had refractory leukemia. Neutropenia was present at the day of IMI diagnosis in 67% of the patients. Sixty-two percent of the patients received prior corticosteroids. The dominant site of infection was the lungs (79%), followed by skin (29%) and sinuses (10%). Seventy-one percent of patients had radiological findings suggestive of fungal pneumonia (either nodules or masses). The mainstay of antifungal therapy was a lipid formulation of amphotericin B. Antifungal therapy resulted in 54% response rate (33% complete) at 12 weeks. The crude 12-week mortality rate was 31%. Logistic regression analysis demonstrated that monocytopenia (P = .013), malnutrition (P = .012), and intensive care admission in the month prior to IMI diagnosis (P = .027) were risk factors for death within 12 weeks. CONCLUSIONS: Although Aspergillus spp. was the most common mold in our pediatric cancer population, the epidemiology of the IMIs was diverse. Adults and children share similar risk factors for and epidemiology of IMIs.
Authors: Rachel L Wattier; Christopher C Dvorak; Jill A Hoffman; Ava A Brozovich; Ibrahim Bin-Hussain; Andreas H Groll; Elio Castagnola; Katherine M Knapp; Theoklis E Zaoutis; Britt Gustafsson; Lillian Sung; David Berman; Natasha B Halasa; Mark J Abzug; Aristea Velegraki; Tanvi S Sharma; Brian T Fisher; William J Steinbach Journal: J Pediatric Infect Dis Soc Date: 2014-07-16 Impact factor: 3.164
Authors: Joanna Klepacka; Zuzanna Zakrzewska; Małgorzata Czogała; Magdalena Wojtaszek-Główka; Emil Krzysztofik; Wojciech Czogała; Szymon Skoczeń Journal: Int J Environ Res Public Health Date: 2022-02-21 Impact factor: 3.390
Authors: Joanna Klepacka; Zuzanna Zakrzewska; Małgorzata Czogała; Magdalena Wojtaszek-Główka; Emil Krzysztofik; Wojciech Czogała; Szymon Skoczeń Journal: Int J Environ Res Public Health Date: 2022-02-02 Impact factor: 3.390